GSK

News

GSK goes all-in on CureVac’s mRNA vaccines

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and

News

Gilead’s twice-yearly HIV PrEP 100% effective, says study

Gilead Sciences’ already dominant position in HIV pre-exposure prophylaxis (PrEP) has been consolidated by a new study showing that its twice-yearly injectable drug was 100% effective in pr

News

GSK et al file appeal to Delaware Zantac order

GSK and other drugmakers have lost no time in filing an appeal to a Delaware court’s decision to allow more than 70,000 Zantac-related lawsuits to go ahead.

R&D

ASCO 2024 - Suzanne Trudel

Sometimes getting a new drug to market is a relatively straight line, but sometimes it’s a winding road.

News

ASCO: DREAMM-8 data puts GSK’s Blenrep back on track

GSK is increasingly confident that its anti-BCMA drug Blenrep could be returned to the US market, after revealing data from the DREAMM-8 trial of the drug in multiple myel

News

GSK shares dive on Zantac court case ruling

Shares in GSK fell around 9% this morning after a judge in a Delaware court gave the green light for tens of thousands of lawsuits claiming harm by gastrointestinal drug Z

GSK goes all-in on CureVac’s mRNA vaccines

Gilead’s twice-yearly HIV PrEP 100% effective, says study

GSK et al file appeal to Delaware Zantac order

ASCO 2024 - Suzanne Trudel

ASCO: DREAMM-8 data puts GSK’s Blenrep back on track

GSK shares dive on Zantac court case ruling

Getting predictive technologies to patients, with Concr

Discover a new era of healthcare panel engagement: Grounded ...

GSK

Editor's Picks